GPCRs in pulmonary arterial hypertension

tipping the balance

Jean Iyinikkel, Fiona Murray (Corresponding Author)

Research output: Contribution to journalReview article

4 Citations (Scopus)
4 Downloads (Pure)

Abstract

Pulmonary arterial hypertension (PAH) is a progressive, fatal disease characterised by increased pulmonary vascular resistance and excessive proliferation of pulmonary artery smooth muscle cells (PASMC). GPCRs, which are attractive pharmacological targets, are important regulators of pulmonary vascular tone and PASMC phenotype. PAH is associated with the altered expression and function of a number of GPCRs in the pulmonary circulation, which leads to the vasoconstriction and proliferation of PASMC and thereby contributes to the imbalance of pulmonary vascular tone associated with PAH; drugs targeting GPCRs are currently used clinically to treat PAH and extensive preclinical work supports the utility of a number of additional GPCRs. Here we review how GPCR expression and function changes with PAH and discuss why GPCRs continue to be relevant drug targets for the disease.
Original languageEnglish
Pages (from-to)3063-3079
Number of pages17
JournalBritish Journal of Pharmacology
Volume175
Issue number15
Early online date17 Apr 2018
DOIs
Publication statusPublished - Aug 2018

Fingerprint

Pulmonary Hypertension
Pulmonary Artery
Smooth Muscle Myocytes
Blood Vessels
Lung
Pulmonary Circulation
Drug Delivery Systems
Vasoconstriction
Vascular Resistance
Pharmacology
Phenotype
Pharmaceutical Preparations

Cite this

GPCRs in pulmonary arterial hypertension : tipping the balance. / Iyinikkel, Jean; Murray, Fiona (Corresponding Author).

In: British Journal of Pharmacology, Vol. 175, No. 15, 08.2018, p. 3063-3079.

Research output: Contribution to journalReview article

@article{9d6a06fa42e3415d8dd54841af8a07e7,
title = "GPCRs in pulmonary arterial hypertension: tipping the balance",
abstract = "Pulmonary arterial hypertension (PAH) is a progressive, fatal disease characterised by increased pulmonary vascular resistance and excessive proliferation of pulmonary artery smooth muscle cells (PASMC). GPCRs, which are attractive pharmacological targets, are important regulators of pulmonary vascular tone and PASMC phenotype. PAH is associated with the altered expression and function of a number of GPCRs in the pulmonary circulation, which leads to the vasoconstriction and proliferation of PASMC and thereby contributes to the imbalance of pulmonary vascular tone associated with PAH; drugs targeting GPCRs are currently used clinically to treat PAH and extensive preclinical work supports the utility of a number of additional GPCRs. Here we review how GPCR expression and function changes with PAH and discuss why GPCRs continue to be relevant drug targets for the disease.",
author = "Jean Iyinikkel and Fiona Murray",
note = "Acknowledgements: This work was supported by grants from the ATS and Wellcome Trust We have no conflict of interest to declare",
year = "2018",
month = "8",
doi = "10.1111/bph.14172",
language = "English",
volume = "175",
pages = "3063--3079",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "15",

}

TY - JOUR

T1 - GPCRs in pulmonary arterial hypertension

T2 - tipping the balance

AU - Iyinikkel, Jean

AU - Murray, Fiona

N1 - Acknowledgements: This work was supported by grants from the ATS and Wellcome Trust We have no conflict of interest to declare

PY - 2018/8

Y1 - 2018/8

N2 - Pulmonary arterial hypertension (PAH) is a progressive, fatal disease characterised by increased pulmonary vascular resistance and excessive proliferation of pulmonary artery smooth muscle cells (PASMC). GPCRs, which are attractive pharmacological targets, are important regulators of pulmonary vascular tone and PASMC phenotype. PAH is associated with the altered expression and function of a number of GPCRs in the pulmonary circulation, which leads to the vasoconstriction and proliferation of PASMC and thereby contributes to the imbalance of pulmonary vascular tone associated with PAH; drugs targeting GPCRs are currently used clinically to treat PAH and extensive preclinical work supports the utility of a number of additional GPCRs. Here we review how GPCR expression and function changes with PAH and discuss why GPCRs continue to be relevant drug targets for the disease.

AB - Pulmonary arterial hypertension (PAH) is a progressive, fatal disease characterised by increased pulmonary vascular resistance and excessive proliferation of pulmonary artery smooth muscle cells (PASMC). GPCRs, which are attractive pharmacological targets, are important regulators of pulmonary vascular tone and PASMC phenotype. PAH is associated with the altered expression and function of a number of GPCRs in the pulmonary circulation, which leads to the vasoconstriction and proliferation of PASMC and thereby contributes to the imbalance of pulmonary vascular tone associated with PAH; drugs targeting GPCRs are currently used clinically to treat PAH and extensive preclinical work supports the utility of a number of additional GPCRs. Here we review how GPCR expression and function changes with PAH and discuss why GPCRs continue to be relevant drug targets for the disease.

U2 - 10.1111/bph.14172

DO - 10.1111/bph.14172

M3 - Review article

VL - 175

SP - 3063

EP - 3079

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 15

ER -